

Update on AMD

1 hour

Steven Ferrucci, OD, FAAO

Description:

This course will discuss some of the newest developments in age-related macular degeneration. Topics such as new treatments for geographic atrophy and the latest anti-VEGF agents are included.

Learning Objectives:

- Review the current treatment options for AMD
- Discuss treatment options that are currently under development for AMD
- Understand the latest treatment options for our patients with AMD

Outline:

1. Introduction
 - a. Prevalence
 - b. Incidence
 - c. Characteristics
2. Nutritional Supplementation
 - a. AREDS
 - i. First large scale study looking at nutrition and ocular health
 - ii. 25% risk reduction in developing advanced AMD in intermediate or worse pts
 - b. AREDS 2
 - i. Looked at lutein, zeaxanthin, and omega 3 on AMD progression
 - ii. Additional 10% in most pts, 26% in some
 - iii. Safer as no beta-carotene
 - c. AREDS 3

- i. Adds B-vitamins
 - 1. Multiple studies support role of B vitamins in reducing AMD incidence and progression
 - 2. Reduced zinc from 80 mg to 25 mg
- 3. Lifestyle
 - a. Smoking
 - b. BMI
 - c. Diet
 - d. UV protection
- 4. Treatment options
 - a. PBM
 - i. Lumithera/Alcon
 - ii. Lightside III results
 - b. Complement inhibitors for GA
 - i. Pegcetocoplan
 - ii. ACP
 - iii. How they work
 - iv. Results/Studies
 - v. When to refer
 - vi. case study
 - c. Anti-Vegf
 - i. How they work
 - ii. Pros/cons
 - iii. The OG
 - 1. Macugen
 - 2. Lucentis
 - 3. Eylea
 - 4. Beovu
 - 5. Avastin

- iv. Newer agents
 - 1. Faricimab
 - 2. High-dose (HD) Eylea
 - 3. Biosimilars
 - 4. Susvimo
- v. In development
 - 1. TKI inhibitors
 - 2. Axpaxli
 - 3. Melatonin?
- d. At home monitoring
 - i. Forsee home
 - ii. Scanly home OCT
 - iii. Okko health
- e. Genetic testing
 - i. Advantages
 - ii. Disadvantages
- 5. When to refer
- 6. Summary/Conclusion(s)